A Phase I Study of Inhaled KB407, a Replication-Incompetent, Non-Integrating Vector Expressing Human Cystic Fibrosis Transmembrane Conductance Regulator (CFTR), for the Treatment of Cystic Fibrosis
Latest Information Update: 16 Aug 2023
At a glance
- Drugs KB 407 (Primary) ; KB 407 (Primary)
- Indications Cystic fibrosis
- Focus Adverse reactions; Proof of concept
- Sponsors Krystal Biotech
- 09 Aug 2023 Status changed from recruiting to withdrawn prior to enrolment.
- 08 May 2023 According to a Krystal Biotech media release, screening activities are ongoing.
- 05 Jun 2022 Planned End Date changed from 30 May 2022 to 30 Oct 2024.